Summit Therapeutics (SMMT) Payables (2016 - 2025)
Historic Payables for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $22.2 million.
- Summit Therapeutics' Payables fell 1984.36% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year decrease of 1984.36%. This contributed to the annual value of $4.6 million for FY2024, which is 7382.83% up from last year.
- Latest data reveals that Summit Therapeutics reported Payables of $22.2 million as of Q3 2025, which was down 1984.36% from $23.0 million recorded in Q2 2025.
- Summit Therapeutics' 5-year Payables high stood at $103.3 million for Q2 2024, and its period low was $710000.0 during Q1 2023.
- Moreover, its 5-year median value for Payables was $6.4 million (2024), whereas its average is $21.5 million.
- Per our database at Business Quant, Summit Therapeutics' Payables crashed by 8979.74% in 2023 and then skyrocketed by 1037011.14% in 2024.
- Summit Therapeutics' Payables (Quarter) stood at $4.4 million in 2021, then skyrocketed by 360.11% to $20.1 million in 2022, then tumbled by 86.75% to $2.7 million in 2023, then skyrocketed by 73.83% to $4.6 million in 2024, then skyrocketed by 379.83% to $22.2 million in 2025.
- Its last three reported values are $22.2 million in Q3 2025, $23.0 million for Q2 2025, and $5.0 million during Q1 2025.